![conference banner](/images/conference-banner.jpeg)
Abstract
The objective of this study was to elucidate an association between Apo- E4 allele and CSF biomarkers Aβ42 and tau for the diagnosis of Alzheimers Disease (AD) patients. Aβ42 and tau protein concentrations in CSF were measured by using ELISA assays. The levels of Aβ42 were found to be decreased where as tau levels increased in AD patients. Moreover in AD patients Apo-E4 allele carriers have shown low Aβ42 levels (328.86 ± 99.0 pg/ml) compared to Apo- E4 allele non-carriers (367.52 ± 57.37 pg/ml), while tau levels were higher in Apo-E4 allele carriers (511 ± 44.67 pg/ml) compared to Apo-E4 allele non-carriers (503.75 ± 41.08 pg/ml). Combination of Aβ42 and tau resulted in sensitivity of 75.38% and specificity of 94.82% and diagnostic accuracy of 84.30% for AD compared with the controls. Therefore low Aβ42 and elevated tau concentrations in CSF may prove to be a better diagnostic marker for AD along with the Apo-E4 allele.
Keywords: Alzheimer's disease, Aβ42, Tau, Apo-E4 allele, cerebrospinal fluid
Current Alzheimer Research
Title: Apo-E4 Allele in Conjunction with Aβ42 and Tau in CSF: Biomarker for Alzheimers Disease
Volume: 8 Issue: 2
Author(s): R. J.L. Kandimalla, S. Prabhakar, B. K. Binukumar, W. Y. Wani, N. Gupta, D. R. Sharma, A. Sunkaria, V. K. Grover, N. Bhardwaj, K. Jain and K. D. Gill1
Affiliation:
Keywords: Alzheimer's disease, Aβ42, Tau, Apo-E4 allele, cerebrospinal fluid
Abstract: The objective of this study was to elucidate an association between Apo- E4 allele and CSF biomarkers Aβ42 and tau for the diagnosis of Alzheimers Disease (AD) patients. Aβ42 and tau protein concentrations in CSF were measured by using ELISA assays. The levels of Aβ42 were found to be decreased where as tau levels increased in AD patients. Moreover in AD patients Apo-E4 allele carriers have shown low Aβ42 levels (328.86 ± 99.0 pg/ml) compared to Apo- E4 allele non-carriers (367.52 ± 57.37 pg/ml), while tau levels were higher in Apo-E4 allele carriers (511 ± 44.67 pg/ml) compared to Apo-E4 allele non-carriers (503.75 ± 41.08 pg/ml). Combination of Aβ42 and tau resulted in sensitivity of 75.38% and specificity of 94.82% and diagnostic accuracy of 84.30% for AD compared with the controls. Therefore low Aβ42 and elevated tau concentrations in CSF may prove to be a better diagnostic marker for AD along with the Apo-E4 allele.
Export Options
About this article
Cite this article as:
J.L. Kandimalla R., Prabhakar S., K. Binukumar B., Y. Wani W., Gupta N., R. Sharma D., Sunkaria A., K. Grover V., Bhardwaj N., Jain K. and D. Gill1 K., Apo-E4 Allele in Conjunction with Aβ42 and Tau in CSF: Biomarker for Alzheimers Disease, Current Alzheimer Research 2011; 8 (2) . https://dx.doi.org/10.2174/156720511795256071
DOI https://dx.doi.org/10.2174/156720511795256071 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
Alzheimer's Disease Drug Development
Alzheimer's disease is a progressive neurodegenerative disorder that affects millions of people worldwide. Despite decades of research, no cure or disease-modifying treatment is available yet. Therefore, the need for developing effective therapies to treat Alzheimer's disease is an urgent matter. This special issue aims to provide a comprehensive overview of ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer’s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Neuronal and Glial Responses to Polyamines in the Ischemic Brain
Current Neurovascular Research Arundic Acid (ONO-2506) Ameliorates Delayed Ischemic Brain Damage by Preventing Astrocytic Overproduction of S100B
Current Drug Targets - CNS & Neurological Disorders Consumption of Polyphenol Plants May Slow Aging and Associated Diseases
Current Pharmaceutical Design Effect of Withania somnifera Supplementation on Rotenone-Induced Oxidative Damage in Cerebellum and Striatum of the Male Mice Brain
Central Nervous System Agents in Medicinal Chemistry Anti-Oxidant Drugs: Novelties and Clinical Implications in Cerebellar Ataxias
Current Neuropharmacology Indole Alkaloids and Semisynthetic Indole Derivatives as Multifunctional Scaffolds Aiming the Inhibition of Enzymes Related to Neurodegenerative Diseases – A Focus on Psychotria L. Genus
Current Topics in Medicinal Chemistry Recent Advances in the Development of Pyrimidine-based CNS Agents
Current Drug Discovery Technologies Understanding the Binding Mechanism of Amyloid-β Inhibitors from Molecular Simulations
Current Pharmaceutical Design Synthesis, Molecular Docking, and Biological Evaluation of Benzimidazole Derivatives as Selective Butyrylcholinesterase Inhibitors
Current Alzheimer Research Vascular Lesion Thickness in the Lenticulostriate Artery Region Serves as a Biomarker for Early Neurological Deterioration
Current Neurovascular Research Therapeutic Role of Zonisamide in Neuropsychiatric Disorders
Mini-Reviews in Medicinal Chemistry Editorial: Statins or Fibrates for the Primary Prevention of Stroke in the Elderly. Faith Makes Some Things Achievable, But Not A
Current Vascular Pharmacology Usefulness of CSF Biomarkers in Predicting the Progression of Amnesic and Nonamnesic Mild Cognitive Impairment to Alzheimer’s Disease
Current Aging Science Development and Evaluation of High Bioavailable Sustained-Release Nimodipine Tablets Prepared with Monolithic Osmotic Pump Technology
Current Drug Delivery Applications of Artificial Neural Networks in Medical Science
Current Clinical Pharmacology COVID-19 and Mental Health
Current Psychiatry Research and Reviews Prevalence and associated factors of sarcopenia in elderly subjects with amnestic mild cognitive impairment or Alzheimer disease.
Current Alzheimer Research Ferulic Acid and Alzheimer’s Disease: Promises and Pitfalls
Mini-Reviews in Medicinal Chemistry Neovascular Age-Related Macular Degeneration and its Association with Alzheimer’s Disease
Current Aging Science Nicotinic Acetylcholine Receptors as Drug Targets
Current Drug Targets - CNS & Neurological Disorders